Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the preceding trading day.

After revenues flattened in the first three months of the year, in the second quarter Gilead saw its total sales fall 6%, largely down to shrinking revenues from its HCV portfolio. Sales shrunk in ...

Covering a total of 91 developing countries, the cut price drugs will be available to more than 100 million people living with hepatitis C. Controversy won't go away Gilead has a treatment access ...

To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

Gilead Sciences (GILD ... Over the past month, shares of this HIV and hepatitis C drugmaker have returned +10.3%, compared to the Zacks S&P 500 composite's -7.4% change. During this period ...

Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence ...